Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma - A Southeastern Cancer Study Group trial

Edwin B. Cox, Charles Vogel, John T. Carpenter, Marilyn Raney

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalInvestigational New Drugs
Volume6
Issue number1
DOIs
StatePublished - Apr 1 1988

Fingerprint

Teniposide
Breast Neoplasms
Neoplasms
Appointments and Schedules
Therapeutics

Keywords

  • breast cancer
  • breast carcinoma
  • teniposide

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma - A Southeastern Cancer Study Group trial. / Cox, Edwin B.; Vogel, Charles; Carpenter, John T.; Raney, Marilyn.

In: Investigational New Drugs, Vol. 6, No. 1, 01.04.1988, p. 37-40.

Research output: Contribution to journalArticle

@article{a904e29cab72475d80345883d3a078f8,
title = "Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma - A Southeastern Cancer Study Group trial",
abstract = "The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.",
keywords = "breast cancer, breast carcinoma, teniposide",
author = "Cox, {Edwin B.} and Charles Vogel and Carpenter, {John T.} and Marilyn Raney",
year = "1988",
month = "4",
day = "1",
doi = "10.1007/BF00170777",
language = "English",
volume = "6",
pages = "37--40",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma - A Southeastern Cancer Study Group trial

AU - Cox, Edwin B.

AU - Vogel, Charles

AU - Carpenter, John T.

AU - Raney, Marilyn

PY - 1988/4/1

Y1 - 1988/4/1

N2 - The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.

AB - The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.

KW - breast cancer

KW - breast carcinoma

KW - teniposide

UR - http://www.scopus.com/inward/record.url?scp=0023938933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023938933&partnerID=8YFLogxK

U2 - 10.1007/BF00170777

DO - 10.1007/BF00170777

M3 - Article

C2 - 3410666

AN - SCOPUS:0023938933

VL - 6

SP - 37

EP - 40

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -